Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jeff C. Hsu"'
Autor:
Peter S. Chang, Yi-Chun Chen, Wei-Kai Hua, Jeff C. Hsu, Jui-Cheng Tsai, Yi-Wun Huang, Yi-Hsin Kao, Pei-Hua Wu, Po-Nan Wang, Yi-Fang Chang, Ming-Chih Chang, Yu-Cheng Chang, Shiou-Ling Jian, Jiann-Shiun Lai, Ming-Tain Lai, Wei-Cheng Yang, Chia-Ning Shen, Kuo-Lan Karen Wen, Sareina Chiung-Yuan Wu
Publikováno v:
PLoS ONE, Vol 19, Iss 8 (2024)
Externí odkaz:
https://doaj.org/article/a24dce73854148dc9828f7489ea2bfaa
Autor:
Yi-Chun Chen, Wei-Kai Hua, Jeff C. Hsu, Peter S. Chang, Kuo-Lan Karen Wen, Yi-Wun Huang, Jui-Cheng Tsai, Yi-Hsin Kao, Pei-Hua Wu, Po-Nan Wang, Ke-Fan Chen, Wan-Ting Liao, Sareina Chiung-Yuan Wu
Chimeric antigen receptor T (CAR-T) cell therapy has the potential to transform cancer treatment. However, CAR-T therapy application is currently limited to certain types of relapsed/refractory B cell lymphomas. To unlock the full potential of CAR-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34433bc4db56d70d58cbc71d1a069abf
https://doi.org/10.1101/2022.05.03.490469
https://doi.org/10.1101/2022.05.03.490469
Autor:
Peter S. Chang, Yi-Chun Chen, Wei-Kai Hua, Jeff C. Hsu, Jui-Cheng Tsai, Yi-Wun Huang, Yi-Hsin Kao, Pei-Hua Wu, Yi-Fang Chang, Ming-Chih Chang, Yu-Cheng Chang, Shiou-Ling Jian, Jiann-Shiun Lai, Ming-Tain Lai, Wei-Cheng Yang, Chia-Ning Shen, Kuo-Lan Karen Wen, Sareina Chiung-Yuan Wu
BackgroundCD19-targeted chimeric antigen receptor therapies (CAR19) have driven a paradigm shift in the treatment of relapsed/refractory B-cell malignancies. However, >50% of CAR19-treated patients experienced progressive disease mainly due to antige
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70c7124184947136f175986840868698
https://doi.org/10.1101/2022.05.03.490475
https://doi.org/10.1101/2022.05.03.490475
Autor:
Wei-Kai Hua, Jeff C. Hsu, Yi-Chun Chen, Peter S. Chang, Kuo-Lan Karen Wen, Po-Nan Wang, Yi-Shan Yu, Ying-Chun Chen, I-Cheng Cheng, Sareina Chiung-Yuan Wu
Recent advances in gene therapy have brought novel treatment options for cancer. However, the full potential of this approach has yet to be unlocked due to the safety concerns and limited payload capacity of commonly utilized viral vectors. Virus-fre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7324bf0db76ad52e77b1a5a179c77828
https://doi.org/10.1101/2022.04.29.490002
https://doi.org/10.1101/2022.04.29.490002
Publikováno v:
Developmental Dynamics. 242:C1-C1